Nebenwirkungen · Simulect
Simulect 20 mg powder and solvent for solution for injection or infusion Simulect 20 mg powder for solution for injection or infusion · Abschnitt 4.8 · PDF-Seite 5
HOS-089008 · Präparat HOS-083755
Incidence of adverse events: In the above four placebo-controlled trials, the pattern of adverse events in 590 patients treated with the recommended dose of basiliximab was comparable to that observed in 595 patients treated with placebo. The overall incidence of treatment-related adverse events among all patients in the individual studies was not significantly different between the basiliximab (7.1% - 40%) and the placebo (7.6% - 39%) treatment groups.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-19T11:51:00Z · SHA-256 733fba3a740348b21107babe9d9387936dfd68357cde53822fb186eb4a9d7e0d · Passage 1ce6a08cad93e17c61950d122830a38bd734ea31426763eb69e0c047ee39654a · Zeichen 659–1116 im Abschnitt